• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Generic and brand-name fluticasone-salmeterol are equally effective in COPD management

byDavid XiangandKiera Liblik
September 18, 2023
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this cohort study, using generic versus brand-name fluticasone-salmeterol was associated with similar outcomes in chronic obstructive pulmonary disease (COPD) patients.

2. Using generic versus brand-name fluticasone-salmeterol was associated with no significant difference in the incidence of COPD exacerbations or pneumonia hospitalizations.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic obstructive pulmonary disease is associated with substantial morbidity and mortality. However, there can be significant costs associated with the high need for inhalers in these patients. In many cases, generic formulations are available which are typically less expensive than brand-name therapeutics. Wixela Inhub was the first generic maintenance inhaler approved for asthma and COPD in the United States. It was U.S. Food and Drug Administration-approved in 2019 with a branded version already produced by GlaxoSmithKline called Advair Diskus. There is a gap in knowledge as to understanding the comparative effectiveness and safety of the generic versus brand-name inhalers for COPD. Overall, this study found that for patients with COPD, the generic fluticasone-salmeterol inhaler, Wixela Inhub, had virtually identical effectiveness and safety when compared with brand-name Advair Diskus. This study was limited by having short follow-up times and by the possibility of residual confounding. Nevertheless, these study’s findings are significant, as they demonstrate that using generic or brand-name fluticasone salmeterol inhalers for COPD management leads to similar outcomes in these patients.

Click to read the study in AIM

Relevant Reading: Comparison of Inhaled Long-Acting β-Agonist and Anticholinergic Effectiveness in Older Patients With Chronic Obstructive Pulmonary Disease

RELATED REPORTS

Patisiran prevents functional decline in patients with cardiac amyloidosis

Amikacin prevents ventilator-associated pneumonia in mechanically ventilated patients

Hypertonic saline stimulation is superior to arginine for diagnosing AVP deficiency

In-Depth [propensity score-matched cohort study]: This 1:1 propensity score-matched cohort study was performed using a large longitudinal healthcare database. Patients who initiated a new (index) prescription for Wixela Inhub or Advair Diskus from 1 January 2018 to 31 June 2021 were eligible for the study. The patients also had to have made at least three outpatient claims or one inpatient claim in the prior three years (up to and including the index date) for a COPD-related diagnosis. Patients who received any other inhaler from the same therapeutic class, who were younger than 40 years, or who initiated triple therapy for COPD were excluded from the study. The primary outcome measured was time to first moderate or severe COPD exacerbation beginning the day after cohort entry. Outcomes in the primary analysis were assessed via 1:1 propensity score matching and used logistic regression with a Cox proportional hazards regression model. Based on the primary analysis, patients who used the Wixela Inhub as compared to patients who used Advair Diskus had a nearly identical incidence of first moderate or severe COPD exacerbation (Hazard Ratio [HR], 0.97; 95% Confidence Interval [CI], 0.90 to 1.04) and first pneumonia hospitalization (HR, 0.99; 95% CI, 0.86 to 1.15). In summary, this study demonstrates that using generic or brand-name fluticasone-salmeterol leads to similar outcomes in patients with COPD treated with routine management.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Advair Diskuschronic diseaseChronic Obstructive Pulmonary Diseasecopdfluticasonefluticasone-salmeterolGlaxoSmithKlineinternal medicinepulmonologyrespirologysalmeterolWixela Inhub
Previous Post

Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy

Next Post

Rectal cancer presentation and screening rates during the COVID-19 pandemic

RelatedReports

Image-guided percutaneous drainage of pericardial effusions is safe and effective
Cardiology

Patisiran prevents functional decline in patients with cardiac amyloidosis

December 8, 2023
Emergency

Amikacin prevents ventilator-associated pneumonia in mechanically ventilated patients

December 7, 2023
Targeted interventions effective in teaching children to swallow pills
Chronic Disease

Hypertonic saline stimulation is superior to arginine for diagnosing AVP deficiency

December 6, 2023
Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

December 5, 2023
Next Post
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Rectal cancer presentation and screening rates during the COVID-19 pandemic

High dose antidepressants may increase self-harm risk among children, young adults

Adverse childhood experiences and current life stressors may moderate the relationship between depression and C-reactive protein in midlife women

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Shohei Sidelined? Blue Light Bust, Sciatica Struggles, and Concussion Effects

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Seriesâ„¢ textbook.

Subscription Options

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific viruses may be associated with increased risk and worse outcomes of ovarian cancer
  • Low-dose amitriptyline effective and well-tolerated for management of irritable bowel syndrome
  • Patisiran prevents functional decline in patients with cardiac amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classicsâ„¢
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options